144 related articles for article (PubMed ID: 11834496)
1. MMP inhibition modulates TNF-alpha transgenic mouse phenotype early in the development of heart failure.
Li YY; Kadokami T; Wang P; McTiernan CF; Feldman AM
Am J Physiol Heart Circ Physiol; 2002 Mar; 282(3):H983-9. PubMed ID: 11834496
[TBL] [Abstract][Full Text] [Related]
2. Myocardial extracellular matrix remodeling in transgenic mice overexpressing tumor necrosis factor alpha can be modulated by anti-tumor necrosis factor alpha therapy.
Li YY; Feng YQ; Kadokami T; McTiernan CF; Draviam R; Watkins SC; Feldman AM
Proc Natl Acad Sci U S A; 2000 Nov; 97(23):12746-51. PubMed ID: 11070088
[TBL] [Abstract][Full Text] [Related]
3. Matrix metalloproteinases in the progression of heart failure: potential therapeutic implications.
Li YY; Feldman AM
Drugs; 2001; 61(9):1239-52. PubMed ID: 11511020
[TBL] [Abstract][Full Text] [Related]
4. Downregulation of matrix metalloproteinases and reduction in collagen damage in the failing human heart after support with left ventricular assist devices.
Li YY; Feng Y; McTiernan CF; Pei W; Moravec CS; Wang P; Rosenblum W; Kormos RL; Feldman AM
Circulation; 2001 Sep; 104(10):1147-52. PubMed ID: 11535571
[TBL] [Abstract][Full Text] [Related]
5. Regulation of matrix metalloproteinases and effect of MMP-inhibition in heart transplant related reperfusion injury.
Falk V; Soccal PM; Grünenfelder J; Hoyt G; Walther T; Robbins RC
Eur J Cardiothorac Surg; 2002 Jul; 22(1):53-8. PubMed ID: 12103373
[TBL] [Abstract][Full Text] [Related]
6. Modulation of airway remodeling-associated mediators by the antifibrotic compound, pirfenidone, and the matrix metalloproteinase inhibitor, batimastat, during acute lung injury in mice.
Corbel M; Lanchou J; Germain N; Malledant Y; Boichot E; Lagente V
Eur J Pharmacol; 2001 Aug; 426(1-2):113-21. PubMed ID: 11525779
[TBL] [Abstract][Full Text] [Related]
7. TNF-alpha and myocardial matrix metalloproteinases in heart failure: relationship to LV remodeling.
Bradham WS; Moe G; Wendt KA; Scott AA; Konig A; Romanova M; Naik G; Spinale FG
Am J Physiol Heart Circ Physiol; 2002 Apr; 282(4):H1288-95. PubMed ID: 11893563
[TBL] [Abstract][Full Text] [Related]
8. Matrix metalloproteinase inhibition after myocardial infarction: a new approach to prevent heart failure?
Creemers EE; Cleutjens JP; Smits JF; Daemen MJ
Circ Res; 2001 Aug; 89(3):201-10. PubMed ID: 11485970
[TBL] [Abstract][Full Text] [Related]
9. Estrogen improves TIMP-MMP balance and collagen distribution in volume-overloaded hearts of ovariectomized females.
Voloshenyuk TG; Gardner JD
Am J Physiol Regul Integr Comp Physiol; 2010 Aug; 299(2):R683-93. PubMed ID: 20504902
[TBL] [Abstract][Full Text] [Related]
10. [Tumor necrosis factor alpha and myocardial matrix metalloproteinases in left ventricular remodeling].
Wang XM; Yang LX; Zhu SJ; Yang YJ; Guo CM; Qi F; Wei L; Shi YK; Wang Y; Ren L
Zhonghua Nei Ke Za Zhi; 2004 Nov; 43(11):828-31. PubMed ID: 15634542
[TBL] [Abstract][Full Text] [Related]
11. Involvement of specific matrix metalloproteinases during tumor necrosis factor/IFNgamma-based cancer therapy in mice.
Van Roy M; Van Lint P; Van Laere I; Wielockx B; Wilson C; López-Otin C; Shapiro S; Libert C
Mol Cancer Ther; 2007 Sep; 6(9):2563-71. PubMed ID: 17876053
[TBL] [Abstract][Full Text] [Related]
12. Combination of tumor necrosis factor-alpha ablation and matrix metalloproteinase inhibition prevents heart failure after pressure overload in tissue inhibitor of metalloproteinase-3 knock-out mice.
Kassiri Z; Oudit GY; Sanchez O; Dawood F; Mohammed FF; Nuttall RK; Edwards DR; Liu PP; Backx PH; Khokha R
Circ Res; 2005 Aug; 97(4):380-90. PubMed ID: 16037568
[TBL] [Abstract][Full Text] [Related]
13. Inhibitor of lysyl oxidase improves cardiac function and the collagen/MMP profile in response to volume overload.
El Hajj EC; El Hajj MC; Ninh VK; Gardner JD
Am J Physiol Heart Circ Physiol; 2018 Sep; 315(3):H463-H473. PubMed ID: 29775412
[TBL] [Abstract][Full Text] [Related]
14. Matrix metalloproteinase activity, bone matrix turnover, and tumor cell proliferation in prostate cancer bone metastasis.
Nemeth JA; Yousif R; Herzog M; Che M; Upadhyay J; Shekarriz B; Bhagat S; Mullins C; Fridman R; Cher ML
J Natl Cancer Inst; 2002 Jan; 94(1):17-25. PubMed ID: 11773278
[TBL] [Abstract][Full Text] [Related]
15. Matrix metalloproteinase inhibition and the prevention of heart failure.
Lee RT
Trends Cardiovasc Med; 2001 Jul; 11(5):202-5. PubMed ID: 11597832
[TBL] [Abstract][Full Text] [Related]
16. Controlling myocardial matrix remodeling: implications for heart failure.
Rao VU; Spinale FG
Cardiol Rev; 1999; 7(3):136-43. PubMed ID: 10423664
[TBL] [Abstract][Full Text] [Related]
17. Targeted overexpression of noncleavable and secreted forms of tumor necrosis factor provokes disparate cardiac phenotypes.
Diwan A; Dibbs Z; Nemoto S; DeFreitas G; Carabello BA; Sivasubramanian N; Wilson EM; Spinale FG; Mann DL
Circulation; 2004 Jan; 109(2):262-8. PubMed ID: 14699008
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of matrix metalloproteinases blocks lethal hepatitis and apoptosis induced by tumor necrosis factor and allows safe antitumor therapy.
Wielockx B; Lannoy K; Shapiro SD; Itoh T; Itohara S; Vandekerckhove J; Libert C
Nat Med; 2001 Nov; 7(11):1202-8. PubMed ID: 11689884
[TBL] [Abstract][Full Text] [Related]
19. Differential expression of MMPs and TIMPs in moderate and severe heart failure in a transgenic model.
Mori S; Gibson G; McTiernan CF
J Card Fail; 2006 May; 12(4):314-25. PubMed ID: 16679266
[TBL] [Abstract][Full Text] [Related]
20. Left ventricular remodeling in transgenic mice with cardiac restricted overexpression of tumor necrosis factor.
Sivasubramanian N; Coker ML; Kurrelmeyer KM; MacLellan WR; DeMayo FJ; Spinale FG; Mann DL
Circulation; 2001 Aug; 104(7):826-31. PubMed ID: 11502710
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
